Lablisa® Human anti-HAV IgG (anti-Hepatitis A antibody IgG) ELISA Kit
Product Information
- Description
- More Infomation
The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human anti-HAV. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human anti-HAV. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Human anti-HAV, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human anti-HAV in the samples is then determined by comparing the OD of the samples to the standard curve.
| Product name: | Lablisa® Human anti-HAV IgG (anti-Hepatitis A antibody IgG) ELISA Kit |
| Reactivity: | Human |
| Alternative Names: | Hepatitis A virus IgG |
| Assay Type: | Sandwich |
| Sensitivity: | 0.063 ng/mL |
| Standard: | 10 ng/mL |
| Detection Range: | 0.16-10 ng/mL |
| Sample type: | serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids |
| Assay length: | 3.5h |
| Research Area: | Infection immunity; |
Standard curve
| Concentration (ng/mL) | OD | Corrected OD |
|---|---|---|
| 10.00 | 2.052 | 1.955 |
| 5.00 | 1.566 | 1.469 |
| 2.50 | 1.102 | 1.005 |
| 1.25 | 0.892 | 0.795 |
| 0.63 | 0.527 | 0.430 |
| 0.32 | 0.336 | 0.239 |
| 0.16 | 0.218 | 0.121 |
| 0.00 | 0.097 | 0.000 |
Precision
Intra-assay Precision (Precision within an assay)：CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays)：CV%<10%
Three samples of known concentration were tested in forty separate assays to assess inter-assay precision.
Recovery
Matrices listed below were spiked with certain level of recombinant anti-HAV and the recovery rates were calculated by comparing the measured value to the expected amount of anti-HAV in samples.
| Matrix | Recovery range | Average |
|---|---|---|
| serum(n=5) | 83-96% | 89% |
| EDTA plasma(n=5) | 80-95% | 87% |
| Heparin plasma(n=5) | 90-105% | 97% |
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of anti-HAV and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Matrix | 1:2 | 1:4 | 1:8 | 1:16 |
|---|---|---|---|---|
| serum(n=5) | 95-103% | 95-103% | 84-98% | 93-102% |
| EDTA plasma(n=5) | 87-98% | 93-105% | 89-97% | 85-97% |
| Heparin plasma(n=5) | 85-92% | 82-96% | 87-105% | 83-92% |
Manuals on the web are for your reference only, specifications are subject to the delivery manuals.
